Last Update: Aug 07, 2025
A Prospective, Non-interventional Study to Evaluate the Efficacy and Safety of Iptacopan in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) in Routine Clinical Practice in the Russian Federation
ClinicalTrials.gov Identifier:
NCT07036718
Novartis Reference Number:CLNP023C1RU03
See if you Pre-qualify
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

This is a prospective, non-interventional, multicenter study to evaluate the efficacy and safety of iptacopan in patients with PNH in real-world settings in Russia.

Paroxysmal Nocturnal Hemoglobinuria
Recruiting
100
Jul 28, 2025
Jan 31, 2028
All
18 Years - (Adult, Older Adult)

Eligibility Criteria

Inclusion Criteria:

1. Age ≥18 years at the start of iptacopan therapy.
2. The patient is undergoing treatment with iptacopan.
3. The treating physician decided to prescribe iptacopan based on the Summary of Product Characteristics during routine clinical practice, regardless of study participation.
4. Provision of written informed consent.

Exclusion Criteria:

1\. Any situations where iptacopan is contraindicated in accordance with the Summary of Product Characteristics.

Novartis Investigative Site

Recruiting

Saint Petersburg,194291,Russia

Novartis Investigative Site

Recruiting

St Petersburg,194291,Russian Federation

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

+41613241111